Schering-Plough drug shortages
Executive Summary
CVS reports industry-wide stocking problems with Schering products. The drug chain had shortages for "two [products] from Schering that they just had trouble producing," CEO Tom Ryan reports during a May 2 conference call. One "was an asthma drug, and it has consistently been a problem not only for CVS but the industry. And we had some shortage around some allergy medication with the ramp-up of the allergy season." Schering markets the asthma drugs Proventil and Vanceril and the allergy medications Claritin and Vancenase. Schering has been experiencing manufacturing problems at its facilities (1"The Pink Sheet" March 5, p. 6)
You may also be interested in...
Claritin Supply Sufficient For Spring, Schering Says; FDA Lists GMP Problems
Schering-Plough will have a sufficient supply of Claritin for the spring allergy season, the company maintains.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials